Revenue
2020
2021
2022
2023
2024
2025
Arcutis Biotherapeutics, Inc. (ARQT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $372.1M | $166.5M | $29.2M | $3.7M | $0 | $0 | — | — |
| Research & development | $77.1M | $76.4M | $110.6M | $182.4M | $145.6M | $115.3M | $36.5M | $17.9M |
| Operating expenses | — | — | — | $305.3M | $206.5M | $136.6M | $43.1M | $19.7M |
| Operating income | −$12.2M | −$128.4M | −$241.1M | −$301.6M | −$206.5M | −$136.6M | −$43.1M | −$19.7M |
| EBITDAderived | −$6.9M | −$125.8M | −$239.6M | −$300.7M | −$206.1M | −$136.5M | — | — |
| Net income | −$16.1M | −$140.0M | −$262.1M | −$311.5M | −$206.4M | −$135.7M | −$42.0M | −$19.3M |
| Basic EPSper diluted share | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | -$15.53 |
| Diluted EPSper diluted share | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 | -$22.78 | -$15.53 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 · 10b5-1 | Welgus Howard G.Director | SellCommon Stock | 635 | $25.67 | $16.3K | 37.7K |
| Jun 15, 2026Form 4 · 10b5-1 | LIN SUE-JEANDirector | SellCommon Stock | 4.9K | $24.38 | $120.6K | 27.6K |
| Jun 15, 2026Form 4 · 10b5-1 | Welgus Howard G.Director | SellCommon Stock | 4.1K | $24.41 | $100.0K | 38.4K |
| May 11, 2026Form 4 · 10b5-1 | Vairavan LathaSVP Chief Financial Officer | SellCommon Stock | 435 | $21.05 | $9.2K | 86.0K |
| May 11, 2026Form 4 · 10b5-1 | Burnett PatrickSee Remarks | SellCommon Stock | 222 | $21.05 | $4.7K | 120.2K |